Harry from United Kingdom

Registered at the short selling broker eToro, 3 minutes ago.

» Try eToro you too
75% of retail investor accounts lose money when trading CFDs with etoro.
Don't show again

Avrobio, Inc. (AVRO) shares information

Avrobio, Inc.


24h Change

-0.21 %

AVRO

Live rate: Market closed

Stock data per Wednesday 25 Nov, 2020

AVRO
NASDAQ
14.03
14.33
14.00
-0.03 (-0.21%)
US Market is closed

Live Stock price in graph for Avrobio, Inc. (AVRO)

  • Latest Volume

    375,022 (-29.16 %)

  • Volume prev. day

    529,360

  • Avg. daily volume

    289,326

  • Market cap

    510,312,600

  • P/E ratio

    -4.25

  • Today high

    14.33 USD

  • Today low

    13.84 USD

  • 52 week high

    29.32 USD

  • 52 week low

    9.76 USD

  • YTD Change

    n/a

Quick links

Broker recommendations for Avrobio

The Avrobio, Inc. stock is rated at 1.125 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Tuesday 10 November, 2020 by a total of 8 brokers. This means that the consensus of the 8 different brokers is leaning toward to buy/moderate buy.

Sell
0 (0%)
Underweight
0 (0%)
Hold
1 (12.5%)
Overweight
0 (0%)
Buy
7 (87.5%)

Price target by analysts

The 7 latest analyst estimates, per Tuesday 17 November, 2020, show the following high, low and average price targets.
Target Average: 37.86 USD
Target High: 58 USD
Target Low: 18 USD

 

Latest news about Avrobio, Inc.

Below you can find the most recent news posts about Avrobio, Inc., primarily from US and UK based news sources.

AVROBIO Announces Closing of Underwritten Public Offering

Tuesday, 24 November 2020, 22:19:00
CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $AVRO–AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock. The aggregate gross proceeds to the company from the offering, before deducting underwriting discounts and commission and estimated offering expenses, totaled $75 million. As previously announced, the company has granted the underwriters a 30-day option to purc
— Business Wire


FY2024 Earnings Forecast for AVROBIO, Inc. (NASDAQ:AVRO) Issued By SVB Leerink

Friday, 20 November 2020, 13:48:42
AVROBIO, Inc. (NASDAQ:AVRO) – Analysts at SVB Leerink raised their FY2024 earnings estimates for AVROBIO in a research note issued to investors on Wednesday, November 18th. SVB Leerink analyst M. Foroohar now forecasts that the company will earn $1.61 per share for the year, up from their previous estimate of $1.60. SVB Leerink has a […]
— Transcript Daily


AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock

Friday, 20 November 2020, 04:06:00
AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,0
— Business Wire


AVROBIO Announces Proposed Public Offering of Common Stock

Thursday, 19 November 2020, 22:09:00
CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $AVRO–AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to $11.25 million of additional shares of its common stock (15 percent) offered in the public offering. All of the shares in the proposed offering are t
— Business Wire


AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

Tuesday, 17 November 2020, 13:00:00
CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $AVRO–AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced positive new data across its clinical programs in Gaucher disease type 1, Fabry disease and cystinosis, further reinforcing the potential of ex vivo lentiviral gene therapy for lysosomal disorders. Additionally, AVROBIO is further expanding its lysosomal disorder pipeline with a new program in Gaucher dis
— Business Wire


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €200
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have AVRO available or trade one of the many other CFD stocks they have.
Risk warning: 75% of retail investor accounts lose money when trading CFDs with Capital.